Calotatug Biosimilar Monoclonal Antibody (HER2) for Research

Cat No.: GMP-Bios-INN-1121

Anti-ERBB2/CD340/HER2 therapeutic antibody (Pre-made Calotatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Calotatug (development code XMT-2056) is an antibody-drug conjugate targeting HER2 (ERBB2) that delivers a STING agonist. It is developed by Mersana Therapeutics for solid tumors. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1121-1mg 1mg 3090
GMP-Bios-INN-1121-10mg 10mg
GMP-Bios-INN-1121-100mg 100mg
GMP-Bios-INN-1121-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Calotatug biosimilar, Whole mAb, Anti-ERBB2/CD340/HER2 Antibody: Anti-HER2/ERBB2/CD340/Receptor tyrosine-protein kinase erbB-2 therapeutic antibody
INN Name Calotatug
Target ERBB2/CD340/HER2
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended 2024
Companies Mersana Therapeutics
Conditions Approved na
Conditions Active Solid tumours
Conditions Discontinued na
Production na
Development Tech na